<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01403506</url>
  </required_header>
  <id_info>
    <org_study_id>186</org_study_id>
    <nct_id>NCT01403506</nct_id>
  </id_info>
  <brief_title>Study of the Effect of N-acetyl Cysteine on the Renal Graft Function Biomarkers (IL18, NGAL)</brief_title>
  <official_title>Phase 3 Study of N-acetyl Cysteine as an Antioxidant and Glutathione Synthesis Inducer on Biomarkers of Delayed Renal Graft Function Including NGAL and IL-18</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shahid Beheshti University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shahid Beheshti University of Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the effect of (NAC) N-Acetyl Cysteine on&#xD;
      biomarkers of Delayed Graft Function (DGF), including Neutrophil Gelatinase Associated&#xD;
      Lipocalin (NGAL) and Intereleukin 18 (IL18).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Kidney transplantation is the best treatment for most patients with end stage renal failure,&#xD;
      but limited numbers of suitable kidneys are available for transplantation. So preservation of&#xD;
      graft is vital. This necessitates the studies and interventions to improve outcome of renal&#xD;
      transplantation surgery.&#xD;
&#xD;
      Delayed Graft Function (DGF) or delay in performance of transplanted kidney means absence of&#xD;
      acceptable function in the renal activity in postgrafting phase. DGF is a consequence of&#xD;
      ischemic and reperfusion injuries (IRI), and oxygen free radicals have a main role in&#xD;
      pathophysiology of DGF. In meta-analysis studies, it has been demonstrated that DGF has a&#xD;
      correlation with long and short time graft survival. Despite great advances in the&#xD;
      transplantation procedure, dysfunction prevalence has not decreased. Major causes of this&#xD;
      problem are the lack of appropriate markers for early diagnosis of DGF and on the other hand&#xD;
      lack of appropriate and effective interventions to controll DGF.&#xD;
&#xD;
      Studies have shown that N-Acetyl Cysteine (NAC) can induce GSH synthesis, scavenger of free&#xD;
      radicals, and infusion of NAC had similar effects as glutathione.&#xD;
&#xD;
      This is a randomized clinical trial (RCT) on patients who have received kidney&#xD;
      transplantation from living donors. Sixty transplanted patients will be randomized into 2&#xD;
      groups. The first group of patients will be treated with NAC 600mg 6 hr before&#xD;
      transplantation and two doses of NAC 12 hours apart after transplantation in addition to&#xD;
      standard treatment, and the second group will receive only standard antirejection treatment.&#xD;
      For all patients entered the study, urinary concentrations of IL18 and NGAL will be measured&#xD;
      in designated times. Risk factors of DGF will be compared in two groups and effectiveness of&#xD;
      NAC in reducing DGF will be determined.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2011</start_date>
  <completion_date type="Anticipated">November 2012</completion_date>
  <primary_completion_date type="Anticipated">April 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>renal function biomarkers (IL18, NGAL)difference between study and control group in 4 and 24 hr after transplantation</measure>
    <time_frame>4 and 24 hrs after renal graft</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>dialysis</measure>
    <time_frame>60 days after transplantation</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Disorder Related to Renal Transplantation</condition>
  <arm_group>
    <arm_group_label>N-Acetyl Cysteine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>N-Acetyl Cysteine: receive N-Acetyl Cysteine in addition to standard treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>standard treatment</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>This group is without N-Acetyl Cysteine : just receives standard treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>N-acetyl Cysteine</intervention_name>
    <description>600 mg N-acetyl Cysteine 6 hrs before renal transplantation, and 12 hrs and 18 hrs after renal transplantation.</description>
    <arm_group_label>N-Acetyl Cysteine</arm_group_label>
    <other_name>Acetylcysteine</other_name>
    <other_name>ACC 600</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patient receiving transplantation from living donors&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  having a neoplastic disease&#xD;
&#xD;
          -  brain tumor&#xD;
&#xD;
          -  having inflammatory diseases in their active phase (SLE)&#xD;
&#xD;
          -  an acute infection, meningitis, sepsis&#xD;
&#xD;
          -  Sickle Cell Disease&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Cardio-renal syndrome&#xD;
&#xD;
          -  endogenous Cushing's syndrome&#xD;
&#xD;
          -  chronic use of cimetidine&#xD;
&#xD;
          -  a history of acute pancreatitis in recent months&#xD;
&#xD;
          -  Multiple Sclerosis&#xD;
&#xD;
          -  cardiac bypass in a recent month&#xD;
&#xD;
          -  cirrhosis due to Hepatitis C&#xD;
&#xD;
          -  having Alzheimer's disease&#xD;
&#xD;
          -  having a untreated major depressive illness or schizophrenia&#xD;
&#xD;
          -  Stroke in recent months&#xD;
&#xD;
          -  Hyperoxaluria&#xD;
&#xD;
          -  sensitivity to sulfonamides&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jamshid Salamzadeh, PhD</last_name>
    <role>Study Director</role>
    <affiliation>SBMU School of Pharmacy, Tehran, Iran</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jamshid Salamzadeh, PhD</last_name>
    <phone>00982188662334</phone>
    <email>j.salamzadeh@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Nephrology, Shahid Labbafinejad Medical Center and Urology and Nephrology Research Center, Shahid Beheshti University of Medical Sciences</name>
      <address>
        <city>Tehran</city>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jamshid Salamzadeh</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mohsen Nafar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>January 2011</verification_date>
  <study_first_submitted>July 25, 2011</study_first_submitted>
  <study_first_submitted_qc>July 26, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 27, 2011</study_first_posted>
  <last_update_submitted>July 26, 2011</last_update_submitted>
  <last_update_submitted_qc>July 26, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 27, 2011</last_update_posted>
  <responsible_party>
    <name_title>Jamshid Salamzadeh/Dr</name_title>
    <organization>Shaheed Beheshti Medical University</organization>
  </responsible_party>
  <keyword>kidney transplantation</keyword>
  <keyword>N-Acetyl Cysteine</keyword>
  <keyword>living donor</keyword>
  <keyword>delayed graft function</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetylcysteine</mesh_term>
    <mesh_term>N-monoacetylcystine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

